Event Details
December 01, 1998
Description
The F.D.A. held a meeting to warn Celgene about its marketing of Thalomid for unapproved uses.
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| Celgene | person | 0 | View Entity |
| F.D.A. | person | 0 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_028418.jpg
This document is a digital article, labeled for a House Oversight investigation, concerning the pharmaceutical company Celgene and its executive, Mr. Hugin. It details the company's aggressive marketing of the drug Thalomid for unapproved uses shortly after its launch, leading to multiple reprimands from the F.D.A. in the late 1990s and a whistle-blower lawsuit settled in 2017. The document is not related to Jeffrey Epstein.
Related Events
Events with shared participants
The F.D.A. approved Celgene's application to treat erythema nodosum leprosum, a complication of leprosy, with its drug Thalomid (thalidomide).
1998-01-01 • United States
Mr. Hugin arrived at Celgene, which was struggling to profit from its only marketed drug, Thalomid.
1999-01-01 • New Jersey
Celgene reported that only 100 prescriptions a year were being written for Thalomid to treat the approved skin condition.
2007-01-01 • United States
Celgene's application was approved by the F.D.A. to treat erythema nodosum leprosum, a complication of leprosy.
1998-01-01 • United States
Mr. Hugin arrived at Celgene while the company was struggling to profit from its only drug, Thalomid.
1999-06-01 • New Jersey
Celgene reported that only about 100 prescriptions per year were written for the approved skin condition (leprosy complication).
2007-01-01 • United States
Celgene reported that 92 percent of Thalomid's prescriptions were being written to treat cancer, despite lack of formal approval for those uses.
2001-01-01
Celgene received formal approval to market Thalomid and Revlimid for certain cancers.
2005-01-01
Revlimid was introduced to the market at an initial cost of about $6,000 per month.
2006-01-01
Celgene settled a lawsuit regarding illegal marketing to avoid protracted litigation.
2017-01-01
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event